JP2009531068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009531068A5 JP2009531068A5 JP2009503126A JP2009503126A JP2009531068A5 JP 2009531068 A5 JP2009531068 A5 JP 2009531068A5 JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009531068 A5 JP2009531068 A5 JP 2009531068A5
- Authority
- JP
- Japan
- Prior art keywords
- ras
- protein
- amino acid
- wild
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000016914 ras Proteins Human genes 0.000 claims 43
- 108010014186 ras Proteins Proteins 0.000 claims 43
- 150000007523 nucleic acids Chemical group 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 108020004707 nucleic acids Proteins 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 24
- 235000018102 proteins Nutrition 0.000 claims 23
- 108090000623 proteins and genes Proteins 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 19
- 235000001014 amino acid Nutrition 0.000 claims 17
- 229940024606 amino acid Drugs 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 101710113436 GTPase KRas Proteins 0.000 claims 13
- 102100039788 GTPase NRas Human genes 0.000 claims 13
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 9
- 239000004471 Glycine Substances 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 229930195712 glutamate Natural products 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 3
- 108090000994 Catalytic RNA Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 101150040459 RAS gene Proteins 0.000 claims 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 108700042226 ras Genes Proteins 0.000 claims 3
- 108091092562 ribozyme Proteins 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000002751 oligonucleotide probe Substances 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78656806P | 2006-03-27 | 2006-03-27 | |
| PCT/US2007/063711 WO2007133835A2 (en) | 2006-03-27 | 2007-03-09 | Ras mutation and compositions and mehods related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198353A Division JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009531068A JP2009531068A (ja) | 2009-09-03 |
| JP2009531068A5 true JP2009531068A5 (enExample) | 2010-04-22 |
Family
ID=38694572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009503126A Pending JP2009531068A (ja) | 2006-03-27 | 2007-03-09 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
| JP2014198353A Pending JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198353A Pending JP2015043773A (ja) | 2006-03-27 | 2014-09-29 | Ｒａｓ変異並びにこれに関連する組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7745128B2 (enExample) |
| EP (1) | EP2004666B1 (enExample) |
| JP (2) | JP2009531068A (enExample) |
| KR (1) | KR20090008290A (enExample) |
| CN (1) | CN101448848B (enExample) |
| AU (1) | AU2007249639B2 (enExample) |
| BR (1) | BRPI0709340A2 (enExample) |
| CA (1) | CA2647102A1 (enExample) |
| MX (1) | MX2008012392A (enExample) |
| SG (1) | SG170763A1 (enExample) |
| TW (1) | TW200806789A (enExample) |
| WO (1) | WO2007133835A2 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002225681A1 (en) * | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| US8343502B2 (en) * | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| WO2007008780A2 (en) * | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| US20070172503A1 (en) * | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
| TW200806789A (en) * | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CN101687030B (zh) * | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| WO2008115610A1 (en) * | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
| ES2685636T3 (es) * | 2007-06-29 | 2018-10-10 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Método de fijación y expresión de sustancia fisiológicamente activa |
| KR100957555B1 (ko) | 2007-12-28 | 2010-05-11 | 덕성여자대학교 산학협력단 | Ｒａｓ 융합 단백질 |
| US20110081362A1 (en) * | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| US20100075326A1 (en) * | 2008-09-12 | 2010-03-25 | Cornell University | Yeast surface two-hybrid system for quantitative detection of protein-protein interactions |
| KR101153845B1 (ko) | 2008-11-10 | 2012-07-09 | 단국대학교 산학협력단 | Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임 |
| EP2350320A4 (en) * | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| JP6010458B2 (ja) * | 2009-04-03 | 2016-10-19 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物 |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US8911722B2 (en) | 2009-09-14 | 2014-12-16 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of yeast-based immunotherapy products and responses |
| WO2011087928A1 (en) * | 2010-01-12 | 2011-07-21 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting kras and pik3ca mutations |
| AU2011223789A1 (en) | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| MX342055B (es) * | 2010-04-12 | 2016-09-12 | Response Genetics Inc | Iniciadores y sondas de kras. |
| AU2011305445B2 (en) | 2010-09-24 | 2017-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
| EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| PE20140844A1 (es) | 2011-02-12 | 2014-07-14 | Globeimmune Inc | Terapeuticos a base de levadura para infeccion de la hepatitis b cronica |
| US9556473B2 (en) | 2011-02-15 | 2017-01-31 | Leica Biosystems Newcastle Ltd | Methods for identifying nucleic acid sequences |
| JP5881746B2 (ja) | 2011-02-15 | 2016-03-09 | ライカ バイオシステムズ ニューキャッスル リミテッド | ｍＲＮＡの局在インサイチュー検出のための方法 |
| JP6068368B2 (ja) | 2011-03-17 | 2017-01-25 | グローブイミューン，インコーポレイテッド | 酵母−ブラキュリ免疫治療組成物 |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| CN102796811B (zh) * | 2011-05-26 | 2013-12-18 | 上海赛安生物医药科技有限公司 | 检测kras突变的试剂及方法 |
| EP2720716B1 (en) | 2011-06-14 | 2018-03-21 | Globeimmune, Inc. | Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection |
| CN109010809A (zh) | 2011-08-17 | 2018-12-18 | 全球免疫股份有限公司 | 酵母-muc1免疫治疗组合物及其用途 |
| EP2776586B1 (en) * | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| US9260714B2 (en) * | 2011-12-02 | 2016-02-16 | Roche Molecular Systems, Inc. | Suppression of non-specific amplification with high-homology oligonucleotides |
| KR101153844B1 (ko) | 2012-04-17 | 2012-06-20 | 단국대학교 산학협력단 | Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임 |
| EP2854779A1 (en) * | 2012-05-31 | 2015-04-08 | Bayer Pharma Aktiengesellschaft | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| KR102103319B1 (ko) * | 2012-06-26 | 2020-04-22 | 바이오디식스, 인크. | 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법 |
| AU2013359469B2 (en) * | 2012-12-10 | 2019-05-16 | Seattle Biomedical Research Institute | Cell-free biofragment compositions and related systems, devices, and methods |
| MX374829B (es) | 2013-03-19 | 2025-03-06 | Globeimmune Inc | Composición a base de levadura para usarse para tratar cordoma. |
| US9782473B2 (en) | 2013-03-26 | 2017-10-10 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human immunodeficiency virus infection |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
| WO2015059677A1 (en) | 2013-10-26 | 2015-04-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Methods of treating cancer |
| BR112016013138A2 (pt) * | 2013-12-09 | 2018-01-16 | Targovax Asa | mistura de peptídeos |
| WO2015123532A1 (en) * | 2014-02-16 | 2015-08-20 | Globeimmune, Inc. | Ras g12r immunotherapy for ras mutation-positive cancers |
| CA2948803A1 (en) * | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| CA2946759A1 (en) | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
| KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
| KR101602870B1 (ko) | 2014-07-22 | 2016-03-21 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용 |
| US10829752B2 (en) * | 2014-08-01 | 2020-11-10 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
| US12415995B2 (en) | 2014-08-01 | 2025-09-16 | Northwestern University | Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders |
| EP3180463B1 (en) * | 2014-08-15 | 2023-08-30 | Medimmune, LLC | Detecting residual host cell proteins in recombinant protein preparations |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| JP2018518177A (ja) * | 2015-06-16 | 2018-07-12 | タルゴバックス エーエスエー | Ｒａｓタンパク質の突然変異フラグメント |
| TWI748957B (zh) | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物 |
| US10612032B2 (en) * | 2016-03-24 | 2020-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inducible production-phase promoters for coordinated heterologous expression in yeast |
| JP2019520086A (ja) | 2016-05-27 | 2019-07-18 | オラム・セラピューティクス・インコーポレイテッド | 細胞質浸透抗体およびその用途 |
| CN118064425A (zh) | 2016-11-16 | 2024-05-24 | 斯坦福大学托管董事会 | 用于鉴定和表达基因簇的系统和方法 |
| MX2019009070A (es) * | 2017-02-01 | 2019-10-30 | Modernatx Inc | Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion. |
| WO2018145020A1 (en) * | 2017-02-03 | 2018-08-09 | The Medical College Of Wisconsin, Inc. | Kras peptide vaccine compositions and method of use |
| EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| JP7722629B2 (ja) * | 2017-07-04 | 2025-08-13 | キュアバック エスイー | 新規核酸分子 |
| CN108250269A (zh) * | 2018-04-02 | 2018-07-06 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440647A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440648A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108484731A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108440646A (zh) * | 2018-04-02 | 2018-08-24 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN108484730A (zh) * | 2018-04-02 | 2018-09-04 | 天津亨佳生物科技发展有限公司 | 一种治疗肿瘤的抗原肽链组及其在药物中的应用 |
| CN119818663A (zh) | 2018-05-15 | 2025-04-15 | 全球免疫公司 | 用于诱导细胞免疫应答的重组酵母裂解物 |
| SG11202012653XA (en) | 2018-06-19 | 2021-01-28 | Biontech Us Inc | Neoantigens and uses thereof |
| KR20190143826A (ko) | 2018-06-21 | 2019-12-31 | 오름테라퓨틱 주식회사 | 세포/조직 특이적 세포 침투 항체 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CA3170359A1 (en) | 2020-04-14 | 2021-10-21 | Nantcell, Inc. | Yeast lysate covid-19 vaccine |
| IL300026A (en) * | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2377188A (en) * | 1941-08-07 | 1945-05-29 | Schering Corp | Stabilized filter preparations |
| US2376884A (en) * | 1941-08-07 | 1945-05-29 | Schering Corp | Hydroquinone composition |
| US3856934A (en) * | 1970-06-24 | 1974-12-24 | A Kligman | Skin depigmentation |
| US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
| US4136166A (en) * | 1977-04-18 | 1979-01-23 | Helena Rubinstein, Inc. | Skin lightening composition |
| US4229427A (en) * | 1978-06-28 | 1980-10-21 | The Procter & Gamble Company | Radioactive scanning agents with hydroquinone stabilizer |
| FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| JPS57145803A (en) * | 1981-03-05 | 1982-09-09 | Sunstar Inc | External decoloring agent for skin |
| US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
| US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US4466955A (en) * | 1982-06-09 | 1984-08-21 | Germaine Monteil Cosmetiques Corporation | Skin bleaching stick containing hydroquinone |
| US4725550A (en) | 1984-01-19 | 1988-02-16 | Research Foundation Of State University Of New York | Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma |
| US5591582A (en) | 1985-07-23 | 1997-01-07 | The Board Of Rijks Universiteit Leiden | Methods for detecting activated RAS oncogenes |
| US4871838A (en) | 1985-07-23 | 1989-10-03 | The Board Of Rijks Universiteit Leiden | Probes and methods for detecting activated ras oncogenes |
| US4792443A (en) * | 1985-12-20 | 1988-12-20 | Warner-Lambert Company | Skin bleaching preparations |
| US5389677B1 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
| JPH0474515A (ja) * | 1990-07-13 | 1992-03-09 | Toray Ind Inc | 酸素吸収体 |
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| US5523077A (en) * | 1992-02-06 | 1996-06-04 | Yale University | Composition and method for whitening skin |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| JPH09500650A (ja) * | 1993-07-26 | 1997-01-21 | ケイ．オー．テクノロジー インコーポレイテッド | ガン治療薬の主薬としての遺伝子の異なる対立遺伝子の阻害剤 |
| GB9422814D0 (en) | 1994-11-11 | 1995-01-04 | Medinnova Sf | Chemical method |
| US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
| US6497860B1 (en) * | 1996-11-04 | 2002-12-24 | Children's Hospital Medical Center | Skin lightening compositions |
| US6060297A (en) * | 1997-04-17 | 2000-05-09 | Incyte Pharmaceuticals, Inc. | Rho protein |
| US5945306A (en) * | 1997-12-16 | 1999-08-31 | Incyte Pharmaceuticals, Inc. | Ras protein |
| US6207450B1 (en) * | 1998-04-15 | 2001-03-27 | University Of Iowa Research Foundation | Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| US6017710A (en) * | 1998-05-13 | 2000-01-25 | Axys Pharmaceuticals, Inc. | RAQ genes and their uses |
| NO309798B1 (no) | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| CA2385134A1 (en) * | 1999-10-15 | 2001-04-19 | Wakenyaku Co., Ltd. | Template molecule having broad applicability and highly efficient function means of cell-free synthesis of proteins by using the same |
| AUPQ495700A0 (en) * | 2000-01-05 | 2000-02-03 | Johnson & Johnson Research Pty. Limited | Method for concurrent amplification and real time detection of polymorphic nucleic acid sequences |
| US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| JP2004508056A (ja) * | 2000-09-06 | 2004-03-18 | グラクソ グループ リミテッド | ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答 |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| US7189759B2 (en) * | 2001-05-23 | 2007-03-13 | Medicis Pharmaceutical Corporation | Compositions for the treatment of pigmentation disorders and methods for their manufacture |
| US6699464B1 (en) * | 2001-07-30 | 2004-03-02 | Stiefel Laboratories, Inc. | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
| GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| US20040185016A1 (en) * | 2002-07-30 | 2004-09-23 | Popp Karl F | Compositions for treatment of hyperpigmentation and methods for making and using such compositions |
| GB0229139D0 (en) * | 2002-12-13 | 2003-01-15 | Glaxo Group Ltd | Gene polymorphisms |
| JP4914990B2 (ja) * | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| WO2007008780A2 (en) | 2005-07-11 | 2007-01-18 | Globeimmune, Inc. | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| TW200806789A (en) * | 2006-03-27 | 2008-02-01 | Globeimmune Inc | RAS mutation and compositions and methods related thereto |
| CN101687030B (zh) | 2007-02-02 | 2014-07-02 | 环球免疫公司 | 用于生产基于酵母的疫苗的方法 |
| WO2008115610A1 (en) | 2007-03-19 | 2008-09-25 | Globeimmune, Inc. | Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer |
-
2007
- 2007-03-09 TW TW096108338A patent/TW200806789A/zh unknown
- 2007-03-09 EP EP07797163.8A patent/EP2004666B1/en not_active Not-in-force
- 2007-03-09 CN CN2007800183814A patent/CN101448848B/zh not_active Expired - Fee Related
- 2007-03-09 KR KR1020087026290A patent/KR20090008290A/ko not_active Ceased
- 2007-03-09 BR BRPI0709340-3A patent/BRPI0709340A2/pt not_active IP Right Cessation
- 2007-03-09 JP JP2009503126A patent/JP2009531068A/ja active Pending
- 2007-03-09 MX MX2008012392A patent/MX2008012392A/es active IP Right Grant
- 2007-03-09 CA CA002647102A patent/CA2647102A1/en not_active Abandoned
- 2007-03-09 SG SG201102095-5A patent/SG170763A1/en unknown
- 2007-03-09 WO PCT/US2007/063711 patent/WO2007133835A2/en not_active Ceased
- 2007-03-09 US US11/684,290 patent/US7745128B2/en active Active
- 2007-03-09 AU AU2007249639A patent/AU2007249639B2/en not_active Ceased
-
2010
- 2010-05-06 US US12/775,267 patent/US8470313B2/en active Active
-
2013
- 2013-03-13 US US13/799,496 patent/US20130344097A1/en not_active Abandoned
-
2014
- 2014-09-29 JP JP2014198353A patent/JP2015043773A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101653555B1 (ko) | 단백질의 분비 생산 방법 | |
| JP6136930B2 (ja) | タンパク質の分泌生産法 | |
| KR20210076082A (ko) | Rna를 편집하기 위한 방법 및 조성물 | |
| KR20260072608A (ko) | 인자 ix의 발현을 위한 조성물 및 방법 | |
| AU2023200122B2 (en) | Tumor-targeting synthetic adenoviruses and uses thereof | |
| JP2017513479A5 (enExample) | ||
| CA3109165A1 (en) | Immunogenic compositions and uses thereof | |
| JP2006081548A5 (enExample) | ||
| CA3109083A1 (en) | Compositions and methods for genome engineering with cas12a proteins | |
| JP2014521313A5 (enExample) | ||
| CN110494567B (zh) | 生产rna的方法 | |
| US20230183754A1 (en) | Systems, methods, and compositions for correction of frameshift mutations | |
| CA3151762A1 (en) | Eukaryotic semi-synthetic organisms | |
| JP2022527705A (ja) | 融合タンパク質およびその使用 | |
| JP2022058603A (ja) | Ｆｃ含有タンパク質の発現 | |
| CA3205126A1 (en) | Rna construct | |
| KR20230145054A (ko) | 조작된 유전자 bbd29_14900의 재조합 균주 및 이의구성 방법 및 적용 | |
| CA3195967A1 (en) | Vectorized anti-tnf-? antibodies for ocular indications | |
| JP2023087682A (ja) | 新規プロモーター | |
| JP2017212911A (ja) | インターロイキン６又はｃｘｃｌ５に起因する疾病の予防又は治療剤をスクリーニングする方法、及びインターロイキン６又はｃｘｃｌ５に起因する疾病の予防又は治療剤 | |
| ES2382207T3 (es) | Procedimiento para la producción de L-glutamina | |
| CN1915433A (zh) | Annexin A3与癌症的铂类化疗药物耐药性的相关性 | |
| KR102655024B1 (ko) | 표적 특이적인 외래 유전자의 도입 방법 | |
| US20090137004A1 (en) | Artificial entropic bristle domain sequences and their use in recombinant protein production | |
| KR101806601B1 (ko) | Mus81-Eme1-DNA 복합체의 3차원 결정구조 및 결정화 방법 |